bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 20, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 30, 2025

Conditions
Liver DiseasesHepatocellular CarcinomaImmunotherapyCamrelizumabLenvatinib
Interventions
PROCEDURE

bTAE-HAIC

bTAE procedure was a 2.8-F microcatheter was superselectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.

DRUG

Lenvatinib

12 mg (or 8 mg) once daily (QD) oral dosing.

DRUG

Camrelizumab

200mg intravenously every 2 weeks

Trial Locations (1)

510000

RECRUITING

Sun Yat-sen University Cancer Center, Guanzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER